Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company’s Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company’s clinical development and medical affairs programs.

Dr. Koneru joins Legend Biotech from Marker Therapeutics, where she served as Chief Medical Officer, leading the development of the company’s cell therapies and peptide vaccines in its immuno-oncology portfolio. Prior to her time at Marker Therapeutics, Dr. Koneru served as Associate Vice President of Immuno-Oncology at Eli Lilly and Company, where she focused on the clinical development of immuno-oncology assets in the company’s early phase oncology portfolio. Prior to Eli Lilly, Dr. Koneru was an Oncology Fellow at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T-cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials.

“On behalf of the Company, I am pleased to welcome Dr. Koneru to the Legend team,” said Ying Huang, CEO of Legend Biotech. “Dr. Koneru brings a wealth of knowledge in the field of immunotherapy and cell therapy, with extensive experience in designing early-stage clinical trials for hematologic malignancies and solid tumors. We look forward to her leadership and contributions to our organization, as we continue to advance our pipeline of cell-based therapies and bring innovative therapies to clinic.”

Dr. Koneru obtained her B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Biomedical Research: Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005132/en/